Atovaquone-proguanil v chloroquine-proguanil for drug attributed gastrointestinal (GI) adverse events and treatment limiting events in participants not immune to malaria†
| Events at 7 days | Atovaquone- proguanil | Chloroquine- proguanil | RRR (95% CI) | NNT (CI) |
|---|---|---|---|---|
| †Abbreviations defined in glossary; RRR, NNT, and CI calculated from data in article. | ||||
| All adverse events | 22% | 28% | 23% (4 to 38) | 16 (9 to 102) |
| Any GI event | 12% | 20% | 41% (21 to 56) | 12 (8 to 28) |
| Nausea | 2% | 7% | 74% (46 to 87) | 20 (13 to 39) |
| Abdominal pain | 3% | 6% | 50% (9 to 73) | 34 (18 to 230) |
| Vomiting | 0 | 2% | 100% (65 to 100) | 46 (26 to 83) |
| Any treatment limiting event | 0.2% | 2% | 90% (40 to 98) | 57 (29 to 162) |
